BELMONT, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- via PRWEB - Xicepta Sciences, Inc., a biotech company in Belmont, CA, launches a molecular medical food, Agitan X, for Parkinson's disease that produces 80% improvement on all symptoms based on the company's case study involving a Parkinson's disease patient. Agitan X contains embryonic peptides from vaccine-grade chicken egg extract with microRNA nucleotides and peptides that replenishes what the disease has depleted in the sufferer's body. It also contains other natural ingredients including Amino Acids and Dopamine properties.
The core research and biotechnology of the embryonic peptide was developed by Dr. Gheorghe Mihaescu, an international expert in the fields of Experimental Immunology in Oncology, Steroid Biochemistry, Radio-assay Methodologies, and Geriatric Nutrition. Dr. Mihaescu has authored 32 published scientific papers in the aforementioned fields and has also performed human clinical studies on the benefits of the embryonic peptides. He also holds 15 invention patents, which have been recognized and prized by the European scientific community at the prestigious Brussels and Geneva Conventions.
The effectiveness of Agitan X in alleviating the disease's symptoms can be attributed to the neuroregenerative function of the factors and the miRNA strands that can be found in the embryonic peptides. These factors cross easily and intact from digestion in the large intestine to the blood stream where they interact and contribute to the renewal of the neural cell life cycle. The rest of the products' natural ingredients are designed to enhance the effectiveness of Agitan X.
Research shows that Parkinson's disease results from lack of dopamine and the degeneration of brain neurons. The symptoms include among others tremors, physical imbalance, muscle rigidity, drooling, and loss of energy. Overtime patients may also exhibit dementia-like symptoms and depression. All of Agitan X's ingredients are formulated to address the disease's symptoms as well as induce cell and tissue repair.
In a case study conducted by Xicepta Sciences, Agitan X was given to Patient A who suffered from Parkinson's disease for over eight years and has degenerated into what may be considered at the last stage of the disease. He exhibited symptoms such as extreme tremors, stuttering, gait imbalance, forgetfulness, depression and has in fact entertained suicidal ideation. Within 30 days after taking Agitan X , Patient A exhibited significant improvement in all areas of Parkinson's disease's core symptoms. After another 45 days, Patient A has gained approximately 80% improvement in all diagnostic axis. Patient A also reported that he now sleeps better, is in much happier mood, has gained back his normal gait and musculature, and even resumed riding his Harley Davidson motorcycle.
Xicepta Sciences is a founder-funded company and it is currently seeking an A-Round funding in order to perform additional studies and bring the product to the global market. Xicepta Sciences owns the exclusive rights to the trade and use of the patented embryonic peptide technology which took over 10 years to test and perfect. Agitan X is available for sale at xicepta.com.
For more information or to schedule an interview regarding the topic, please contact Dr. Soledad M. Manaay, President and CEO of Xicepta Sciences, Inc. at 650-771-7676 or at dr(dot)manaay(at)xicepta(dot)com.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/04/prweb12681294.htm
Xicepta Sciences, Inc. Soledad M Manaay, PhD +1 650-771-7676
